Neumora Therapeutics, Inc. ($NMRA)
Filing Information
| Accession Number | 0001610717-26-000385 |
|---|---|
| Form Type | 4 |
| Filing Date | Aug 21, 2026 |
| Document | View SEC Filing |
Transactions
15
Total Shares
728,180
Total Value
$396,730.17
P&L
+inf% (+$326,000.00)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chief Operating and Development Officer | Common Stock | โ | Aug 20, 2026 | Exercise/Conversion | 67,741 | $0.72 | $48,773.52 | 116,491 | Direct | โ | View Details | |
Chief Operating and Development Officer | Common Stock | โ | Aug 20, 2026 | Sale | 67,741 | $1.51 | $102,586.97 | 48,750 | Direct | โ | View Details | |
Chief Operating and Development Officer | Common Stock | โ | Aug 20, 2026 | Exercise/Conversion | 21,685 | $0.72 | $15,613.20 | 21,685 | Indirect | See footnote | View Details | |
Chief Operating and Development Officer | Common Stock | โ | Aug 20, 2026 | Exercise/Conversion | 45,026 | $0.72 | $32,418.72 | 66,711 | Indirect | See footnote | View Details | |
Chief Operating and Development Officer | Common Stock | โ | Aug 20, 2026 | Sale | 66,711 | $1.51 | $101,000.45 | 0 | Indirect | See footnote | View Details | |
Chief Operating and Development Officer | Common Stock | โ | Aug 21, 2026 | Exercise/Conversion | 20,553 | $0.72 | $14,798.16 | 69,303 | Direct | โ | View Details | |
Chief Operating and Development Officer | Common Stock | โ | Aug 21, 2026 | Sale | 20,553 | $1.59 | $32,779.98 | 48,750 | Direct | โ | View Details | |
Chief Operating and Development Officer | Common Stock | โ | Aug 21, 2026 | Exercise/Conversion | 21,055 | $0.72 | $15,159.60 | 21,055 | Indirect | See footnote | View Details | |
Chief Operating and Development Officer | Common Stock | โ | Aug 21, 2026 | Sale | 21,055 | $1.60 | $33,599.57 | 0 | Indirect | See footnote | View Details | |
Chief Operating and Development Officer | Stock Option (Right to Buy) | Derivative | Aug 20, 2026 | Exercise/Conversion | 67,741 | $0.00 | $0.00 | 109,527 | Direct | โ | View Details | |
Chief Operating and Development Officer | Stock Option (Right to Buy) | Derivative | Aug 20, 2026 | Exercise/Conversion | 45,026 | $0.00 | $0.00 | 0 | Indirect | See footnote | View Details | |
Chief Operating and Development Officer | Stock Option (Right to Buy) | Derivative | Aug 20, 2026 | Exercise/Conversion | 21,685 | $0.00 | $0.00 | 115,853 | Indirect | See footnote | View Details | |
Chief Operating and Development Officer | Stock Option (Right to Buy) | Derivative | Aug 20, 2026 | Grant/Award | 200,000 | $0.00 | $0.00 | 200,000 | Direct | โ | View Details | |
Chief Operating and Development Officer | Stock Option (Right to Buy) | Derivative | Aug 21, 2026 | Exercise/Conversion | 20,553 | $0.00 | $0.00 | 88,974 | Direct | โ | View Details | |
Chief Operating and Development Officer | Stock Option (Right to Buy) | Derivative | Aug 21, 2026 | Exercise/Conversion | 21,055 | $0.00 | $0.00 | 94,798 | Indirect | See footnote | View Details |